Page last updated: 2024-10-25

ci 994 and Neutropenia

ci 994 has been researched along with Neutropenia in 1 studies

tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
" There are several strategies for increasing dose intensity, one being a protracted daily dosing strategy without major dose reduction for toxicity."1.31Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. ( Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE, 2000)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keyes, KA1
Albella, B1
LoRusso, PM1
Bueren, JA1
Parchment, RE1

Other Studies

1 other study available for ci 994 and Neutropenia

ArticleYear
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating;

2000